{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:36:20Z","timestamp":1790678180932,"version":"4.1.0"},"reference-count":30,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T00:00:00Z","timestamp":1580083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T00:00:00Z","timestamp":1580083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"ReViral Ltd"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,1,27]]},"abstract":"<jats:p>Effective treatments for respiratory syncytial virus (RSV) infection are lacking. Here, we report a human proof-of-concept study for RV521, a small-molecule antiviral inhibitor of the RSV-F protein. In this randomized, double-blind, placebo-controlled trial, healthy adults were challenged with RSV-A Memphis-37b.<\/jats:p>","DOI":"10.1128\/aac.01884-19","type":"journal-article","created":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T05:46:23Z","timestamp":1573451183000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":87,"title":["A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein"],"prefix":"10.1128","volume":"64","author":[{"given":"John","family":"DeVincenzo","sequence":"first","affiliation":[{"name":"University of Tennessee Center for Health Sciences, Memphis, Tennessee, USA"},{"name":"Children\u2019s Foundation Research Institute at LeBonheur Children\u2019s Hospital, Memphis, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dereck","family":"Tait","sequence":"additional","affiliation":[{"name":"ReViral Ltd., Stevenage, Hertfordshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Efthimiou","sequence":"additional","affiliation":[{"name":"Independent Respiratory Specialist, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Mori","sequence":"additional","affiliation":[{"name":"hVIVO Services Limited, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-In","family":"Kim","sequence":"additional","affiliation":[{"name":"University of Tennessee Center for Health Sciences, Memphis, Tennessee, USA"},{"name":"Children\u2019s Foundation Research Institute at LeBonheur Children\u2019s Hospital, Memphis, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Thomas","sequence":"additional","affiliation":[{"name":"ReViral Ltd., Stevenage, Hertfordshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Wilson","sequence":"additional","affiliation":[{"name":"ReViral Ltd., Stevenage, Hertfordshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Harland","sequence":"additional","affiliation":[{"name":"ReViral Ltd., Stevenage, Hertfordshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Mathews","sequence":"additional","affiliation":[{"name":"ReViral Ltd., Stevenage, Hertfordshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Cockerill","sequence":"additional","affiliation":[{"name":"ReViral Ltd., Stevenage, Hertfordshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Powell","sequence":"additional","affiliation":[{"name":"ReViral Ltd., Stevenage, Hertfordshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Littler","sequence":"additional","affiliation":[{"name":"ReViral Ltd., Stevenage, Hertfordshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-1218-z"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.13.3.371-384.2000"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu828"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30938-8"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis211"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.2.179"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.5.9906076"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200406-730OC"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043951"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014-1665"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/2049936116630243"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1401184"},{"key":"e_1_3_3_14_2","unstructured":"Martin JA Osterman MJK. 2018. Describing the increase in preterm births in the United States 2014\u20132016. National Center for Health Statistics Hyattsville MD. https:\/\/www.cdc.gov\/nchs\/data\/databriefs\/db312.pdf."},{"key":"e_1_3_3_15_2","unstructured":"U.S. Food and Drug Administration. 2017. Respiratory syncytial virus infection: developing antiviral drugs for prophylaxis and treatment guidance for industry. U.S. Food and Drug Administration Rockville MD. https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM579756.pdf."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12503"},{"key":"e_1_3_3_17_2","volume-title":"255th Am Chem Soc Natl Meeting","author":"Cockerill GS","year":"2018","unstructured":"Cockerill GS, Bedernjak A, Brookes D, Dowey R, Harland R, Johnson SM, Mathews N, Paradowski M, Peeples M, Scott C, Steadman M, Taylor G, Thom M, Thomas E, Ward SE, Watterson D, Young P, Powell K. 2018. Design, identification and clinical progression of RV521, an inhibitor of respiratory syncytial virus fusion. 255th Am Chem Soc Natl Meeting, New Orleans, LA."},{"key":"e_1_3_3_18_2","volume-title":"Am Thorac Soc 2018 Intl Conf","author":"DeVincenzo J","year":"2018","unstructured":"DeVincenzo J, Tait D, Oluwayi K, Mori J, Thomas E, Mathews N, Harland R, Cockerill S, Powell K, Littler E. 2018. Safety and efficacy of oral RV521 in a human respiratory syncytial virus (RSV) phase 2a challenge study. Am Thorac Soc 2018 Intl Conf, San Diego, CA."},{"key":"e_1_3_3_19_2","unstructured":"European Medicines Agency. 2018. Guideline on the clinical evaluation of medicinal products indicated for the prophylaxis or treatment of respiratory syncytial virus (RSV) disease. European Medicines Agency Amsterdam Netherlands. https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/guideline-clinical-evaluation-medicinal-products-indicated-prophylaxis-treatment-respiratory_en.pdf."},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1413275"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy227"},{"key":"e_1_3_3_22_2","first-page":"A4457","article-title":"A phase 2b, randomized, double-blind, placebo-controlled trial of presatovir (GS-5806), a novel oral RSV fusion inhibitor, for the treatment of respiratory syncytial virus (RSV) in hospitalized adults","volume":"197","author":"Hanfelt-Goade D","year":"2018","unstructured":"Hanfelt-Goade D, Maimon N, Nimer A, Riviere F, Catherinot E, Ison M, Jeong SH, Walsh E, Gafter-Gvili A, Nama SR, Napora P, Chowers M, Bergeron A, Zeltser D, Moudgil H, Limaye AP, Couturaud F, Nseir W, McKevitt M, Porter D, Jordan R, Guo Y, German P, Watkins TR, Gossage DL, Chien JW, Falsey AR. 2018. A phase 2b, randomized, double-blind, placebo-controlled trial of presatovir (GS-5806), a novel oral RSV fusion inhibitor, for the treatment of respiratory syncytial virus (RSV) in hospitalized adults. Am J Respir Crit Care Med 197:A4457.","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv133.901"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00170-x"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2017.07.017"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/pr.2017.173"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201002-0221OC"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113100"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716197"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2629"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.5.2356-2362.2005"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01884-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01884-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:07:38Z","timestamp":1645466858000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01884-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,27]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,1,27]]}},"alternative-id":["10.1128\/AAC.01884-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.01884-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,27]]},"assertion":[{"value":"2019-09-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01884-19"}}